• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

What is the Relationship Between Age at Natural Menopause and Incidence of Cardiovascular Disease?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Zhu et al. (The Lancet, 2019) sought to determine the relationship between onset of menopause and cardiovascular (CVD) risk

METHODS:

  • Pooled analysis of individual-level data from observational studies
    • Data derived from the International Collaboration for a Life Course Approach to Reproductive Health and Chronic Disease Events (InterLACE), a consortium of pooled individual-level data on reproductive health and chronic diseases
    • 15 studies were used across 5 countries/regions (Australia, Scandinavia, the USA, Japan, and the UK) from 1946 to 2013
  • Participants
    • Women who reported their menopause status, age at natural menopause (if postmenopausal), and CVD status (including coronary heart disease and stroke)
    • Exclusion: History of hysterectomy or oophorectomy
  • Groups
    • Premenopausal or perimenopausal
    • <40 years (premature menopause)
    • 40–44 years (early menopause)
    • 45–49 years (relatively early)
    • 50–51 years (reference category)
    • 52–54 years (relatively late)
    • ≥55 years or older (late menopause)
  • Definitions
    • CVD: Composite outcome of incident coronary heart disease (including heart attack and angina)
    • Stroke: Ischemic or stroke
  • Data analysis
    • Cox proportional hazards models to estimate multivariate hazard ratio (HR) and 95% CI
    • Adjusted for confounders, including smoking status, menopausal hormone therapy status, BMI, and education levels
  • Primary outcome
    • Occurrence of first non-fatal cardiovascular disease or stroke

RESULTS:

  • 301,438 women were included
    • First non-fatal CVD event after menopause:4.3%
      • Coronary heart disease: 3.1%
      • Stroke: 1.4%
  • Compared to reference category, risk of CVD was
    • Higher in women who had premature menopause (p<0.0001)
      • <40 years: HR 1.55 (95% CI, 1.38 to 1.73)
    • Higher in women who had early menopause (p<0.0001)
      • 40–44 years: HR 1.30 (95% CI, 1.22 to 1.39)
    • Higher in women who had relatively early menopause (p<0.0001)
      • 45–49 years HR 1.12 (95% CI, 1.07 to 118)
    • Reduced in women with late menopause
      • >51 years: HR 0.88 (95% CI, 0.83 to 0.93; p<0·0001)
  • Smoking did not alter the above associations
  • The associations were strongest for CVD events before age 60 for women with
    • Premature menopause: HR 1.88 (95% CI, 1.62 to 2.20; p<0.0001)
    • Early menopause: HR 1.40 (95% CI, 1.27 to 1.54; p<0.0001)
    • However, the associations were attenuated at age 60–69 years and no longer present for events ≥70 years
  • Women with early or premature onset who took HT for at least 10 years had lower risk for CVD compared to no HT or less than 10 years
    • In addition, menopausal HT initiation 1 year after menopause resulted in lower CVD risk than when HT was started more than 1 year after menopause

CONCLUSION:

  • Premature and early menopause are associated with an increased risk of CVD prior to 70 years when compared to the reference range (50-51 years)
  • Clinical implications of this study include
    • Women with early menopause may benefit from closer surveillance and active management of CVD risk factors  
    • Consideration of early menopause as a CVD risk factor
    • Encourage prevention strategies such as smoking cessation and maintaining normal BMI to reduce risk for early menopause

Learn More – Primary Sources:

Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Early-Onset Menopause – Increased Risk of Cardiovascular Disease?
Practical info on evidence based medicine for your women's healthcare practice
Does Estrogen Therapy Have Cardiovascular Benefit in Early Postmenopause?
What is the Effect of High-Intensity Training on Diabetes and Cardiovascular Disease in Menopause?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site